How long has axitinib been on the market in China?

Axitinib/Axitinib was developed by Pfizer under the trade name Inlyta. It was initially approved by the US FDA in 2012 for the treatment of advanced renal cell carcinoma (RCC). It has since been gradually approved for marketing in many countries around the world. In mainland China, axitinib was approved by the National Medical Products Administration (NMPA) in December 2018. Its main indication is patients with advanced renal cell carcinoma who have failed one systemic treatment in the past.

Axitinib has been on the market in China for more than six years sinceit was officially approved in 2018. In the past six years, its use scenarios have gradually expanded, clinical experience has continued to accumulate, and certain progress has been made in medical insurance negotiations, making patient accessibility stronger year by year. Especially after 2020, with the rise of immune combination therapy, axitinib has become one of the core drugs in multiple first-line treatment options, and its market attention and academic status have increased significantly.

It is worth noting that the review process for new targeted drugs in the Chinese market is constantly accelerating. Anti-tumor drugs such as axitinib, which have been widely used abroad, have been significantly shortened in domestic approval time in recent years, bringing more choices to patients. Moreover, axitinib has gradually become an important option for patients with renal cancer who have failed previous treatments in clinical practice in China due to its oral administration, clear targeting, and stable efficacy.

Currently, axitinib is mainly sold in China by Pfizer, and is covered in the medical insurance directories of multiple provinces and cities. The financial pressure on patients to obtain drugs has also gradually decreased, improving their accessibility in second-line and even first-line treatments. In the future, as more immune combination therapies become available, the application scenarios of axitinib are expected to further expand and become one of the "cornerstone drugs" in the management of advanced solid tumors.

Reference materials:https://en.wikipedia.org/wiki/Axitinib